Phase 2 Relapsed Multiple Myeloma Clinical Trials
4 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–4 of 4 trials
Recruiting
Phase 2
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Benjamin T Diamond, MD30 enrolled1 locationNCT05896228
Recruiting
Phase 1Phase 2
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
Relapsed Multiple Myeloma
PETHEMA Foundation60 enrolled15 locationsNCT05060627
Recruiting
Phase 2
MM25: A phase 1b/II study of the efficacy of Venetoclax, Iberdomide and Dexamethasone (IberVenD) for patients in first or second relapse of Multiple Myeloma with t(11;14)
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Australasian Leukaemia & Lymphoma Group50 enrolled1 locationACTRN12622001158752
Not Yet Recruiting
Phase 2
A First-in-Human Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Ichnos Sciences SA121 enrolled8 locationsACTRN12622000856718